taking a break from tirzepatide Some people opt to pause drugs used for weight loss over the holidays. Is it safe? Is it safe to transition

The table utilizes clinical evidence from trials measuring appetite scores and food consumption over a designated time frame

However, cardiac death was higher in the febuxostat group

The IJO review correctly observes that absolute lean mass losses on GLP-1 therapy are modest typically 14% from baseline

In: KhanARatherMAAshrafGM, editors

GLP-1R has emerged as a key therapeutic target in obesity and diabetes research, inspiring the development of dual and triple receptor agonists that synergistically enhance glycemic control, promote weight loss, and improve overall metabolic health

As mentioned earlier, the manufacturer of Mounjaro recommends that patients remain on the treatment for at least three years